Iovance Biotherapeutics, Inc. (IOVA)

Market Cap	901.02M
Revenue (ttm)	241.53M
Net Income (ttm)	-389.92M
Shares Out	361.85M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,230,117
Open	2.230
Previous Close	2.200
Day's Range	2.229 - 2.500
52-Week Range	1.639 - 12.505
Beta	0.82
Analysts	Buy
Price Target	11.90 (+377.91%)
Earnings Date	Nov 6, 2025

About IOVA

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 838
• Stock Exchange: NASDAQ
• Ticker Symbol: IOVA
• Website: https://www.iovance.com

Financial Performance

In 2024, Iovance Biotherapeutics's revenue was $164.07 million, an increase of 13698.99% compared to the previous year's $1.19 million. Losses were -$372.18 million, -16.18% less than in 2023.

Analyst Summary

According to 11 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $11.9, which is an increase of 377.91% from the latest price.

Price Target

$11.9

(377.91% upside)

Analyst Consensus: Buy